ESR1 and breast cancer: Here, we assessed the Mcl-1 inhibitor VU661013 in ER+ breast cancer cells, finding that VU661013 induced caspase activity, inhibited growth, and induced apoptosis of ER+ breast cancer cells in culture and in vivo.